Arkolith/Insider Trading/AYTU/Form 4

Pyszczymuka Greg

Chief Commercial OfficerAYTU BIOPHARMA, INC (AYTU) · full profile →Form 4 · filed Jan 2, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 31, 2024Option exercise(M)208——23K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 31, 2024Option exercise(M)208—$0209

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000912282-25-000018) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML